Safety and Effectiveness of Edoxaban in Atrial Fibrillation Patients in Routine Clinical Practice: One-Year Follow-Up from the Global Noninterventional ETNA-AF Program

Lignende værker

• The global Edoxaban Treatment in routine cliNical prActice (ETNA) noninterventional study program: rationale and design
  af: De Caterina, Raffaele, et al.
  Udgivet: (2019)
• Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe)
  af: De Caterina, Raffaele, et al.
  Udgivet: (2019)
• Postmarketing surveillance on the clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF‐Japan): One‐year safety and effectiveness analyses
  af: Takeshi Yamashita, et al.
  Udgivet: (2020-06-01)
• Postmarketing surveillance on the clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF‐Japan): One‐year safety and effectiveness analyses
  af: Yamashita, Takeshi, et al.
  Udgivet: (2020)
• Impact of Weight on Clinical Outcomes of Edoxaban Therapy in Atrial Fibrillation Patients Included in the ETNA-AF-Europe Registry
  af: Boriani, Giuseppe, et al.
  Udgivet: (2021)